Paul Hagedoorn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Paul Hagedoorn has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Henderik Willem Frijlink
Department of Pharmaceutical Technology and Biopharmacy, Groningen Research Institute of Pharmacy, Faculty of Science and Engineering, University of Groningen, 9713 AV Groningen, The Netherlands
12 shared publications - Floris Grasmeijer
Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
6 shared publications - Anne H. de Boer
Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, 9713 AV Groningen, The Netherlands
5 shared publications - Anne J. Lexmond
Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, The Netherlands
5 shared publications - Nick H. T. Ten Hacken
Department of Pulmonary Diseases, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands
5 shared publications - Claire Alette Cox
Department of Pulmonary Diseases, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
3 shared publications
Latest Publications
- Open Access
- 2 September 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (9) , 1149
An In Vitro–In Vivo Comparison of Two Levodopa Dry Powder Products for Inhalation: A Randomized Trial Comparing Inbrija and Levodopa Cyclops
Background/Objectives: The pulmonary administration of levodopa enables a rapid absorption and onset of action, making it a suitable administration route for managing OFF episodes in Parkinson’s disease. Currently, one dry powder product for inhalation (Inbrija) is available on the market, while another (Levodopa Cyclops) is in development. These two products differ substantially in terms of inhaler design, their use and resistance, and their powder formulations. This study aimed to investigate whether these differences translate into in vitro differences in aerosol characteristics and dissolution kinetics and whether any differences were also reflected in the in vivo performance. Methods: The in vitro aerosol characteristics were determined via Next Generation Impactor experiments, and the dissolution kinetics were determined with a modified paddle apparatus. A randomized crossover comparative bioavailability study with fasted healthy volunteers was conducted with Inbrija 84 mg and Levodopa Cyclops 45 mg, 90 mg, and 135 mg. Results: The results showed similar aerosol characteristics, but Levodopa Cyclops showed substantially faster dissolution behavior than Inbrija. Despite this in vitro difference, the pharmacokinetic profiles of Inbrija 84 mg and Levodopa Cyclops 90 mg were similar, with no differences in Cmax, Tmax, and AUC, showing bioequivalence between the two products. Conclusions: This suggests that the systemic absorption of levodopa via the lungs is not limited by dissolution but most likely by its permeation rate. This finding underscores the need to critically apply in vitro tests and critically interpret the results for predicting the in vivo performance of inhaled products.
- 2 September 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (9) , 1149
Open AccessAn In Vitro–In Vivo Comparison of Two Levodopa Dry Powder Products for Inhalation: A Randomized Trial Comparing Inbrija and Levodopa Cyclops
Background/Objectives: The pulmonary administration of levodopa enables a rapid absorption and onset of action, making it a suitable administration route for managing OFF episodes in Parkinson’s disease. Currently, one dry powder product for inhalation (Inbrija) is available on the market, while another (Levodopa Cyclops) is in development. These two products differ substantially in terms of inhaler design, their use and resistance, and their powder formulations. This study aimed to investigate whether these differences translate into in vitro differences in aerosol characteristics and dissolution kinetics and whether any differences were also reflected in the in vivo performance. Methods: The in vitro aerosol characteristics were determined via Next Generation Impactor experiments, and the dissolution kinetics were determined with a modified paddle apparatus. A randomized crossover comparative bioavailability study with fasted healthy volunteers was conducted with Inbrija 84 mg and Levodopa Cyclops 45 mg, 90 mg, and 135 mg. Results: The results showed similar aerosol characteristics, but Levodopa Cyclops showed substantially faster dissolution behavior than Inbrija. Despite this in vitro difference, the pharmacokinetic profiles of Inbrija 84 mg and Levodopa Cyclops 90 mg were similar, with no differences in Cmax, Tmax, and AUC, showing bioequivalence between the two products. Conclusions: This suggests that the systemic absorption of levodopa via the lungs is not limited by dissolution but most likely by its permeation rate. This finding underscores the need to critically apply in vitro tests and critically interpret the results for predicting the in vivo performance of inhaled products.
- Open Access
- 7 March 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (3) , 347
Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin in Children with Cystic Fibrosis
Background: Pseudomonas aeruginosa (Pa) is the predominant pulmonary pathogen in persons with Cystic Fibrosis (CF). Nebulization with tobramycin or colistin is mostly applied but has a significant treatment burden. Dry powder (DP) inhalation may offer an attractive alternative. The aim of this study was to assess local tolerability and the systemic pharmacokinetic parameters of increasing doses of dry powder tobramycin. Methods: This was a local tolerability and pharmacokinetic evaluation pilot study DP tobramycin of three different doses inhaled through the Cyclops (30, 60, 120 mg) in ten persons with CF, aged 6–18 years, compared to nebulization of tobramycin solution. Results: Both nebulization of tobramycin in solution and inhalation of dry powder tobramycin were well tolerated. None of the participants showed a significant drop in FEV1 after inhalation. The only two adverse events were cough and bad taste in, respectively, 20% and 13% of all inhalations, compared to 10% cough and 60% bad taste with nebulization. Systemic tobramycin levels were not detected after 30 mg, detected only in 10% after 60 mg and in 30% after 120 mg, compared to 80% after nebulization. Conclusions: Inhalation of dry powder tobramycin using the Cyclops is well tolerated, with no significant drop in FEV1, and only mild adverse events of cough and bad taste. We found only a few detectable systemic tobramycin levels after inhalation of dry powder tobramycin. We recommend that future studies should focus on the relation between dose and inhaler resistance in different pediatric age groups.
- 7 March 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (3) , 347
Open AccessTolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin in Children with Cystic Fibrosis
Background: Pseudomonas aeruginosa (Pa) is the predominant pulmonary pathogen in persons with Cystic Fibrosis (CF). Nebulization with tobramycin or colistin is mostly applied but has a significant treatment burden. Dry powder (DP) inhalation may offer an attractive alternative. The aim of this study was to assess local tolerability and the systemic pharmacokinetic parameters of increasing doses of dry powder tobramycin. Methods: This was a local tolerability and pharmacokinetic evaluation pilot study DP tobramycin of three different doses inhaled through the Cyclops (30, 60, 120 mg) in ten persons with CF, aged 6–18 years, compared to nebulization of tobramycin solution. Results: Both nebulization of tobramycin in solution and inhalation of dry powder tobramycin were well tolerated. None of the participants showed a significant drop in FEV1 after inhalation. The only two adverse events were cough and bad taste in, respectively, 20% and 13% of all inhalations, compared to 10% cough and 60% bad taste with nebulization. Systemic tobramycin levels were not detected after 30 mg, detected only in 10% after 60 mg and in 30% after 120 mg, compared to 80% after nebulization. Conclusions: Inhalation of dry powder tobramycin using the Cyclops is well tolerated, with no significant drop in FEV1, and only mild adverse events of cough and bad taste. We found only a few detectable systemic tobramycin levels after inhalation of dry powder tobramycin. We recommend that future studies should focus on the relation between dose and inhaler resistance in different pediatric age groups.
- Open Access
- 28 June 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (7) , 1847
Performance Testing of a Homemade Aerosol Generator for Pulmonary Administration of Dry Powder Formulations to Mice
A challenge in the development of dry powder formulations for inhalation is the poor reproducibility of their administration to small laboratory animals. The currently used devices for the pulmonary administration of dry powder formulations to small rodents often function sub-optimally as they use the same puff of air for both powder dispersion and aerosol delivery. As a result, either the air volume and flow rate are too low for complete powder deagglomeration or they are too high for effective aerosol delivery to the lungs of the animal. Therefore, novel and better devices are desired. We here present an aerosol generator designed to administer a pre-generated aerosol to the lungs of mice. By mapping the complex relationship between the airflow rate, delivery time and emitted dose, we were able to control the amount of powder being delivered from the aerosol generator. The emitted aerosol had a size range favorable for lung deposition and could be measured reproducibly. Nevertheless, in vivo fluorescent imaging still revealed considerable differences between the mice in terms of the dose deposited and the distribution of powder over the lungs, suggesting that a certain biological variation in lung deposition is inevitable.
- 28 June 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (7) , 1847
Open AccessPerformance Testing of a Homemade Aerosol Generator for Pulmonary Administration of Dry Powder Formulations to Mice
A challenge in the development of dry powder formulations for inhalation is the poor reproducibility of their administration to small laboratory animals. The currently used devices for the pulmonary administration of dry powder formulations to small rodents often function sub-optimally as they use the same puff of air for both powder dispersion and aerosol delivery. As a result, either the air volume and flow rate are too low for complete powder deagglomeration or they are too high for effective aerosol delivery to the lungs of the animal. Therefore, novel and better devices are desired. We here present an aerosol generator designed to administer a pre-generated aerosol to the lungs of mice. By mapping the complex relationship between the airflow rate, delivery time and emitted dose, we were able to control the amount of powder being delivered from the aerosol generator. The emitted aerosol had a size range favorable for lung deposition and could be measured reproducibly. Nevertheless, in vivo fluorescent imaging still revealed considerable differences between the mice in terms of the dose deposited and the distribution of powder over the lungs, suggesting that a certain biological variation in lung deposition is inevitable.
- 16 June 2023
- Published by Springer Nature
- p. 299-335
Pulmonary
- Open Access
- 28 January 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (2) , 320
Performance of Tablet Splitters, Crushers, and Grinders in Relation to Personalised Medication with Tablets
Swallowing problems and the required dose adaptations needed to obtain optimal pharmacotherapy may be a hurdle in the use of tablets in daily clinical practice. Tablet splitting, crushing, or grinding is often applied to personalise medication, especially for the elderly and children. In this study, the performance of different types of (commercially available) devices was studied. Included were splitters, screwcap crushers, manual grinders, and electric grinders. Unscored tablets without active ingredient were prepared, with a diameter of 9 and 13 mm and a hardness of 100–220 N. Tablets were split into two parts and the difference in weight was measured. The time needed to pulverise the tablets (crush time) was recorded. The residue remaining in the device (loss) was measured. The powder was sieved to obtain a particle fraction >600 µm and <600 µm. The median particle size and particle size distribution of the later fraction were determined using laser diffraction analysis. Splitting tablets into two equal parts appeared to be difficult with the devices tested. Most screwcap grinders yielded a coarse powder containing larger chunks. Manual and especially electric grinders produced a finer powder, making it suitable for administration via an enteral feeding tube as well as for use in individualised preparations such as capsules. In conclusion, for domestic and incidental use, a screwcap crusher may provide sufficient size reduction, while for the more demanding regular use in hospitals and nursing residences, a manual or electric grinder is preferred.
- 28 January 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (2) , 320
Open AccessPerformance of Tablet Splitters, Crushers, and Grinders in Relation to Personalised Medication with Tablets
Swallowing problems and the required dose adaptations needed to obtain optimal pharmacotherapy may be a hurdle in the use of tablets in daily clinical practice. Tablet splitting, crushing, or grinding is often applied to personalise medication, especially for the elderly and children. In this study, the performance of different types of (commercially available) devices was studied. Included were splitters, screwcap crushers, manual grinders, and electric grinders. Unscored tablets without active ingredient were prepared, with a diameter of 9 and 13 mm and a hardness of 100–220 N. Tablets were split into two parts and the difference in weight was measured. The time needed to pulverise the tablets (crush time) was recorded. The residue remaining in the device (loss) was measured. The powder was sieved to obtain a particle fraction >600 µm and <600 µm. The median particle size and particle size distribution of the later fraction were determined using laser diffraction analysis. Splitting tablets into two equal parts appeared to be difficult with the devices tested. Most screwcap grinders yielded a coarse powder containing larger chunks. Manual and especially electric grinders produced a finer powder, making it suitable for administration via an enteral feeding tube as well as for use in individualised preparations such as capsules. In conclusion, for domestic and incidental use, a screwcap crusher may provide sufficient size reduction, while for the more demanding regular use in hospitals and nursing residences, a manual or electric grinder is preferred.
- Open Access
Turning green: the impact of changing to more eco-friendly respiratory healthcare. A carbon and cost analysis of Dutch prescription data
Objectives Dry powder inhalers (DPIs) and soft mist inhalers have a substantially lower global warming potential than pressurized metered-dose inhalers (pMDIs). To help mitigate climate change, we assessed the potential emission reduction in CO2-equivalents when replacing pMDIs by non-propellant inhalers in Dutch respiratory healthcare, and estimated the associated costs. Design We performed a four-step analysis based on data from two national databases of two independent governmental bodies (the Dutch National Healthcare Institute and the Dutch Healthcare Authority). First, we calculated the number of patients with chronic obstructive pulmonary disease and asthma that were using inhalation medication (2020). Second, we calculated the number and total of daily defined doses of pMDIs and non-propellant inhalers (NPIs) that include dry powder inhalers and soft mist inhalers, as well as the number of spacers per patient dispensed by non-hospital based pharmacies in 2020. Third, we estimated the potential reduction in greenhouse gas emission if 70% of patients would switch from using pMDIs to using NPIs as eco-friendly alternatives. Fourth, we performed a budget impact analysis. Results In 2020, 1.4 million patients used inhalers for COPD or asthma treatment. A total of 460 million defined daily doses (DDDs) from inhalers were dispensed, of which – after the exclusion of nebulizers – 50.4% through pMDIs. We estimated that this usage could be reduced by 70% which would lead to an annual reduction in greenhouse gas emission of 77 - 84 million kg. CO2eq. saving at best EUR 49.8 million per year. Conclusions In the Netherlands, substitution of pMDIs to NPIs for eligible patients is theoretically safe and in accordance with medical guidelines, while reducing greenhouse gas emission by 80 million kg. CO2eq. on average and saving at best EUR 49.8 million per year. This study confirms the potential climate and economic benefit of delivering a more eco-friendly respiratory care. Strengths and limitations of this study Given availability and reliability of the data, the present analysis can easily be replicated elsewhere which allows for international comparison and aggregation. Implementation challenges remain underexposed.
Open AccessTurning green: the impact of changing to more eco-friendly respiratory healthcare. A carbon and cost analysis of Dutch prescription data
Objectives Dry powder inhalers (DPIs) and soft mist inhalers have a substantially lower global warming potential than pressurized metered-dose inhalers (pMDIs). To help mitigate climate change, we assessed the potential emission reduction in CO2-equivalents when replacing pMDIs by non-propellant inhalers in Dutch respiratory healthcare, and estimated the associated costs. Design We performed a four-step analysis based on data from two national databases of two independent governmental bodies (the Dutch National Healthcare Institute and the Dutch Healthcare Authority). First, we calculated the number of patients with chronic obstructive pulmonary disease and asthma that were using inhalation medication (2020). Second, we calculated the number and total of daily defined doses of pMDIs and non-propellant inhalers (NPIs) that include dry powder inhalers and soft mist inhalers, as well as the number of spacers per patient dispensed by non-hospital based pharmacies in 2020. Third, we estimated the potential reduction in greenhouse gas emission if 70% of patients would switch from using pMDIs to using NPIs as eco-friendly alternatives. Fourth, we performed a budget impact analysis. Results In 2020, 1.4 million patients used inhalers for COPD or asthma treatment. A total of 460 million defined daily doses (DDDs) from inhalers were dispensed, of which – after the exclusion of nebulizers – 50.4% through pMDIs. We estimated that this usage could be reduced by 70% which would lead to an annual reduction in greenhouse gas emission of 77 - 84 million kg. CO2eq. saving at best EUR 49.8 million per year. Conclusions In the Netherlands, substitution of pMDIs to NPIs for eligible patients is theoretically safe and in accordance with medical guidelines, while reducing greenhouse gas emission by 80 million kg. CO2eq. on average and saving at best EUR 49.8 million per year. This study confirms the potential climate and economic benefit of delivering a more eco-friendly respiratory care. Strengths and limitations of this study Given availability and reliability of the data, the present analysis can easily be replicated elsewhere which allows for international comparison and aggregation. Implementation challenges remain underexposed.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64)
Comparing five antistatic valved holding chambers: how antistatic are they really?
Background: valved holding chambers are known to be non-interchangeable, but their antistatic counterparts are generally regarded as equally antistatic. Methods: in this study we test this supposition by measuring the in vitro delivered doses of salbutamol (Ventolin®) and beclomethasone (Qvar®) from five antistatic valved holding chambers (Aerochamber PlusTM Flow-VuTM, Compact Space Chamber PlusTM, InspiraChamberTM, OptiChamber DiamondTM and VortexTM) used without (i.e. ‘rinsed’) and with a detergent coating (i.e. ‘drip dried’). Results: delivered doses of salbutamol and beclomethasone from the Compact Space Chamber PlusTM and InspiraChamberTM are improved by up to a factor two by drip drying, indicating that the antistatic properties of these antistatic valved holding chambers are suboptimal. Drip drying of the Aerochamber PlusTM Flow-VuTM, OptiChamber DiamondTM and VortexTM on the other hand did not significantly affect the delivered doses of both drugs from these devices, indicating that their antistatic properties are optimal. Of the latter three, the delivered doses from the OptiChamber DiamondTM were consistently lower, which therefore must be caused by differences in its shape or size, or a different functioning of its valve. Conclusions: some ‘antistatic’ valved holding chambers are only poorly antistatic. As a result, antistatic valved holding chambers are non-interchangeable, which means that switching between them should be discouraged.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64)
Comparing five antistatic valved holding chambers: how antistatic are they really?
Background: valved holding chambers are known to be non-interchangeable, but their antistatic counterparts are generally regarded as equally antistatic. Methods: in this study we test this supposition by measuring the in vitro delivered doses of salbutamol (Ventolin®) and beclomethasone (Qvar®) from five antistatic valved holding chambers (Aerochamber PlusTM Flow-VuTM, Compact Space Chamber PlusTM, InspiraChamberTM, OptiChamber DiamondTM and VortexTM) used without (i.e. ‘rinsed’) and with a detergent coating (i.e. ‘drip dried’). Results: delivered doses of salbutamol and beclomethasone from the Compact Space Chamber PlusTM and InspiraChamberTM are improved by up to a factor two by drip drying, indicating that the antistatic properties of these antistatic valved holding chambers are suboptimal. Drip drying of the Aerochamber PlusTM Flow-VuTM, OptiChamber DiamondTM and VortexTM on the other hand did not significantly affect the delivered doses of both drugs from these devices, indicating that their antistatic properties are optimal. Of the latter three, the delivered doses from the OptiChamber DiamondTM were consistently lower, which therefore must be caused by differences in its shape or size, or a different functioning of its valve. Conclusions: some ‘antistatic’ valved holding chambers are only poorly antistatic. As a result, antistatic valved holding chambers are non-interchangeable, which means that switching between them should be discouraged.
- Open Access
- 9 July 2020
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (7) , 645
Automated Filling Equipment Allows Increase in the Maximum Dose to Be Filled in the Cyclops® High Dose Dry Powder Inhalation Device While Maintaining Dispersibility
In recent years there has been increasing interest in the pulmonary delivery of high dose dry powder drugs, such as antibiotics. Drugs in this class need to be dosed in doses far over 2.5 mg, and the use of excipients should therefore be minimized. To our knowledge, the effect of the automatic filling of high dose drug formulations on the maximum dose that can be filled in powder inhalers, and on the dispersion behavior of the powder, have not been described so far. In this study, we aimed to investigate these effects after filling with an Omnidose, a vacuum drum filler. Furthermore, the precision and accuracy of the filling process were investigated. Two formulations were used—an isoniazid formulation we reported previously and an amikacin formulation. Both formulations could be precisely and accurately dosed in a vacuum pressure range of 200 to 600 mbar. No change in dispersion was seen after automatic filling. Retention was decreased, with an optimum vacuum pressure range found from 400 to 600 mbar. The nominal dose for amikacin was 57 mg, which resulted in a fine particle dose of 47.26 ± 1.72 mg. The nominal dose for isoniazid could be increased to 150 mg, resulting in a fine particle dose of 107.35 ± 13.52 mg. These findings may contribute to the understanding of the upscaling of high dose dry powder inhalation products.
- 9 July 2020
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (7) , 645
Open AccessAutomated Filling Equipment Allows Increase in the Maximum Dose to Be Filled in the Cyclops® High Dose Dry Powder Inhalation Device While Maintaining Dispersibility
In recent years there has been increasing interest in the pulmonary delivery of high dose dry powder drugs, such as antibiotics. Drugs in this class need to be dosed in doses far over 2.5 mg, and the use of excipients should therefore be minimized. To our knowledge, the effect of the automatic filling of high dose drug formulations on the maximum dose that can be filled in powder inhalers, and on the dispersion behavior of the powder, have not been described so far. In this study, we aimed to investigate these effects after filling with an Omnidose, a vacuum drum filler. Furthermore, the precision and accuracy of the filling process were investigated. Two formulations were used—an isoniazid formulation we reported previously and an amikacin formulation. Both formulations could be precisely and accurately dosed in a vacuum pressure range of 200 to 600 mbar. No change in dispersion was seen after automatic filling. Retention was decreased, with an optimum vacuum pressure range found from 400 to 600 mbar. The nominal dose for amikacin was 57 mg, which resulted in a fine particle dose of 47.26 ± 1.72 mg. The nominal dose for isoniazid could be increased to 150 mg, resulting in a fine particle dose of 107.35 ± 13.52 mg. These findings may contribute to the understanding of the upscaling of high dose dry powder inhalation products.
- Open Access
- 25 December 2019
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (1) , 24
Dispersibility and Storage Stability Optimization of High Dose Isoniazid Dry Powder Inhalation Formulations with L-Leucine or Trileucine
Tuberculosis is the leading cause of death from a single infectious pathogen worldwide. Lately, the targeted delivery of antibiotics to the lungs via inhalation has received increasing interest. In a previous article, we reported on the development of a spray-dried dry powder isoniazid formulation containing an L-leucine coating. It dispersed well but had poor physical stability. In this study, we aimed to improve the stability by improving the leucine coating. To this end, we optimized the spray-drying conditions, the excipient content, and the excipient itself. Using L-leucine, the tested excipient contents (up to 5%) did not result in a stable powder. Contrary to L-leucine, the stability attained with trileucine was satisfactory. Even when exposed to 75% relative humidity, the formulation was stable for at least three months. The optimal formulation contained 3% trileucine w/w. This formulation resulted in a maximum fine particle dose of 58.00 ± 2.56 mg when a nominal dose of 80 mg was dispersed from the Cyclops® dry powder inhaler. The improved moisture protection and dispersibility obtained with trileucine are explained by its amorphous nature and a higher surface enrichment during drying. Dispersion efficiency of the device decreases at higher nominal doses.
- 25 December 2019
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (1) , 24
Open AccessDispersibility and Storage Stability Optimization of High Dose Isoniazid Dry Powder Inhalation Formulations with L-Leucine or Trileucine
Tuberculosis is the leading cause of death from a single infectious pathogen worldwide. Lately, the targeted delivery of antibiotics to the lungs via inhalation has received increasing interest. In a previous article, we reported on the development of a spray-dried dry powder isoniazid formulation containing an L-leucine coating. It dispersed well but had poor physical stability. In this study, we aimed to improve the stability by improving the leucine coating. To this end, we optimized the spray-drying conditions, the excipient content, and the excipient itself. Using L-leucine, the tested excipient contents (up to 5%) did not result in a stable powder. Contrary to L-leucine, the stability attained with trileucine was satisfactory. Even when exposed to 75% relative humidity, the formulation was stable for at least three months. The optimal formulation contained 3% trileucine w/w. This formulation resulted in a maximum fine particle dose of 58.00 ± 2.56 mg when a nominal dose of 80 mg was dispersed from the Cyclops® dry powder inhaler. The improved moisture protection and dispersibility obtained with trileucine are explained by its amorphous nature and a higher surface enrichment during drying. Dispersion efficiency of the device decreases at higher nominal doses.
- Open Access
- 13 May 2019
- Published by MDPI AG in Pharmaceutics
- Vol. 11 (5) , 233
Characterization and Formulation of Isoniazid for High-Dose Dry Powder Inhalation
Tuberculosis is a major health problem and remains one of the main causes of mortality. In recent years, there has been an increased interest in the pulmonary delivery of antibiotics to treat tuberculosis. Isoniazid is one of these antibiotics. In this study, we aimed to characterize isoniazid and formulate it into a dry powder for pulmonary administration with little or no excipient, and for use in the disposable Twincer® inhaler. Isoniazid was jet milled and spray dried with and without the excipient l-leucine. Physiochemical characterization showed that isoniazid has a low Tg of −3.99 ± 0.18 °C and starts to sublimate around 80 °C. Milling isoniazid with and without excipients did not result in a suitable formulation, as it resulted in a low and highly variable fine particle fraction. Spray drying pure isoniazid resulted in particles too large for pulmonary administration. The addition of 5% l-leucine resulted in a fraction ®. However, storage stability was poor at higher relative humidity, which likely results from dissolution-crystallization. Therefore, follow up research is needed to further optimize this spray dried formulation.
- 13 May 2019
- Published by MDPI AG in Pharmaceutics
- Vol. 11 (5) , 233
Open AccessCharacterization and Formulation of Isoniazid for High-Dose Dry Powder Inhalation
Tuberculosis is a major health problem and remains one of the main causes of mortality. In recent years, there has been an increased interest in the pulmonary delivery of antibiotics to treat tuberculosis. Isoniazid is one of these antibiotics. In this study, we aimed to characterize isoniazid and formulate it into a dry powder for pulmonary administration with little or no excipient, and for use in the disposable Twincer® inhaler. Isoniazid was jet milled and spray dried with and without the excipient l-leucine. Physiochemical characterization showed that isoniazid has a low Tg of −3.99 ± 0.18 °C and starts to sublimate around 80 °C. Milling isoniazid with and without excipients did not result in a suitable formulation, as it resulted in a low and highly variable fine particle fraction. Spray drying pure isoniazid resulted in particles too large for pulmonary administration. The addition of 5% l-leucine resulted in a fraction ®. However, storage stability was poor at higher relative humidity, which likely results from dissolution-crystallization. Therefore, follow up research is needed to further optimize this spray dried formulation.